The Role of RNA Methylation Modification Related Genes in Prognosis and Immunotherapy of Colorectal Cancer

References

• La Vecchia S, Sebastián C. Metabolic pathways regulating colorectal cancer initiation and progression. Semi Cell Dev Biol. 2020;98:63–70.
   PubMed Web of Science ®Google Scholar
• Miller KD, Nogueira L, Mariotto AB, et al. Cancer treatment and survivorship statistics. CA Cancer J Clin. 2019;69(5):363–385.
   PubMed Web of Science ®Google Scholar
• Sigalotti L, Covre A, Fratta E, et al. Epigenetics of human cutaneous melanoma: setting the stage for new therapeutic strategies. J Transl Med. 2010;11(8):56.
   Google Scholar
• Wang X, Lu Z, Gomez A, et al. N6-methyladenosine-dependent regulation of messenger RNA stability. Nature. 2014;505(7481):117–120.
   PubMed Web of Science ®Google Scholar
• Sigrid N, Chuan H. The emerging biology of RNA post-transcriptional modifications. RNA Biol. 2017;14(2):156–163.
   PubMed Web of Science ®Google Scholar
• Lui L, Lowe T. Small nucleolar RNAs and RNA-guided post-transcriptional modification. Essays Biochem. 2013;54:53–77.
   PubMed Web of Science ®Google Scholar
• Shi Q, Xue C, Yuan X, He Y, Yu Z. Gene signatures and prognostic values of m1A-related regulatory genes in hepatocellular carcinoma. Sci Rep. 2020;10(1):15083.
   PubMed Web of Science ®Google Scholar
• Wang P, Wu M, Tu Z, et al. Identification of RNA: 5-Methylcytosine Methyltransferases-Related Signature for Predicting Prognosis in Glioma. Front Oncol. 2020;10:1119.
   PubMed Web of Science ®Google Scholar
• Zheng R, Zhang K, Tan S, et al. Exosomal circLPAR1 functions in colorectal cancer diagnosis and tumorigenesis through suppressing BRD4 via METTL3-eIF3h interaction. Mol Cancer. 2022;21(1):49.
   PubMed Web of Science ®Google Scholar
• Jiang Z, Li S, Han MJ, Hu GM, C P. High expression of NSUN5 promotes cell proliferation via cell cycle regulation in colorectal cancer. Am J Transl Res. 2020;12(7):3858–3870.
   PubMed Web of Science ®Google Scholar
• Zhou M, Liu W, Zhang J, Sun N. RNA m(6)A Modification in Immunocytes and DNA Repair: the Biological Functions and Prospects in Clinical Application. Front Cell Dev Biol. 2021;9:794754.
   PubMed Web of Science ®Google Scholar
• Chen Z, Qi M, Shen B, et al. Transfer RNA demethylase ALKBH3 promotes cancer progression via induction of tRNA-derived small RNAs. Nucleic Acids Res. 2019;47(5):2533–2545.
   PubMed Web of Science ®Google Scholar
• He Y, Yu X, Li J, Zhang Q, Zheng Q, G W. Role of m5C-related regulatory genes in the diagnosis and prognosis of hepatocellular carcinoma. Am J Transl Res. 2020;12(3):912–922.
   PubMed Web of Science ®Google Scholar
• Pan J, Huang Z, Xu Y. m5C-Related lncRNAs Predict Overall Survival of Patients and Regulate the Tumor Immune Microenvironment in Lung Adenocarcinoma. Front Cell Dev Biol. 2021;9:671821.
   PubMed Web of Science ®Google Scholar
• Li W, Gao Y, Jin X, et al. Comprehensive analysis of N6-methyladenosine regulators and m6A-related RNAs as prognosis factors in colorectal cancer. Mol Ther Nucleic Acids. 2022;27:598–610.
   PubMedGoogle Scholar
• Gorzo A, Galos D, Volovat SR, Lungulescu CV, Burz C, Sur D. Landscape of Immunotherapy Options for Colorectal Cancer: current Knowledge and Future Perspectives beyond Immune Checkpoint Blockade. Life. 2022;12(2):229.
   PubMedGoogle Scholar
• Boccaletto P, Machnicka MA, Purta E, et al. MODOMICS: a database of RNA modification pathways. 2017 update. Nucleic Acids Res. 2018;46(D1):D303–D307.
   PubMed Web of Science ®Google Scholar
• Zheng S, Han H, Lin S. N(6)-methyladenosine (m(6)A) RNA modification in tumor immunity. Cancer Biol Med. 2022;8:534.
   Google Scholar
• Manna S. An overview of pentatricopeptide repeat proteins and their applications. Biochimie. 2015;113:93–99.
   PubMed Web of Science ®Google Scholar
• Cui J, Wang L, Ren X, Zhang Y, Zhang H. LRPPRC: a Multifunctional Protein Involved in Energy Metabolism and Human Disease. Front Physiol. 2019;10:595.
   PubMed Web of Science ®Google Scholar
• Hou J, Wang F, M WL. Molecular cloning and expression of the gene for a major leucine-rich protein from human hepatoblastoma cells (HepG2). Vitro Cell Dev Biol Anim. 1994;30A(2):111–114.
   PubMed Web of Science ®Google Scholar
• Zhang HY, Ma YD, Zhang Y, Cui J, Wang ZM. Elevated levels of autophagy-related marker ULK1 and mitochondrion-associated autophagy inhibitor LRPPRC are associated with biochemical progression and overall survival after androgen deprivation therapy in patients with metastatic prostate cancer. J Clin Pathol. 2017;70(5):383–389.
   PubMed Web of Science ®Google Scholar
• Gao W, Xua J, Wang F, et al. Mitochondrial Proteomics Approach Reveals Voltage-Dependent Anion Channel 1 (VDAC1) as a Potential Biomarker of Gastric Cancer. Cell Physiol Biochem. 2015;37(6):2339–2354.
   PubMed Web of Science ®Google Scholar
• Tian T, Ikeda J, Wang Y, et al. Role of leucine-rich pentatricopeptide repeat motif-containing protein (LRPPRC) for anti-apoptosis and tumourigenesis in cancers. Eur J Cancer. 2012;48(15):2462–2473.
   PubMed Web of Science ®Google Scholar
• Nishio T, Kurabe N, Goto-Inoue N, et al. Immunohistochemical expression analysis of leucine-rich PPR-motif-containing protein (LRPPRC), a candidate colorectal cancer biomarker identified by shotgun proteomics using iTRAQ. Clin Chim Acta. 2017;471:276–282.
   PubMed Web of Science ®Google Scholar
• Jiang X, Zhong W, Huang H, et al. Autophagy defects suggested by low levels of autophagy activator MAP1S and high levels of autophagy inhibitor LRPPRC predict poor prognosis of prostate cancer patients. Mol Carcinog. 2015;54(10):1194–1204.
   PubMed Web of Science ®Google Scholar
• Zou J, Yue F, Jiang X, Li W, Yi J, Liu L. Mitochondrion-associated protein LRPPRC suppresses the initiation of basal levels of autophagy via enhancing Bcl-2 stability. Biochem J. 2013;454(3):447–457.
   PubMed Web of Science ®Google Scholar
• Liu JY, Chen YJ, Feng HH, et al. LncRNA SNHG17 interacts with LRPPRC to stabilize c-Myc protein and promote G1/S transition and cell proliferation. Cell Death Dis. 2021;12(11):970.
   PubMed Web of Science ®Google Scholar
• Iguchi T, Ueda M, Masuda T, et al. Identification of UHRF2 as a Negative Regulator of Epithelial-Mesenchymal Transition and Its Clinical Significance in Esophageal Squamous Cell Carcinoma. Oncology. 2018;95(3):179–187.
   PubMed Web of Science ®Google Scholar
• Jin C, Xiong D, Li HR, Jiang JH, Qi JC, Ding JY. Loss of UHRF2 Is Associated With Non-small Cell Lung Carcinoma Progression. J Cancer. 2018;9(17):2994–3005.
   PubMed Web of Science ®Google Scholar
• Lu S, Yan D, Wu Z, et al. Ubiquitin-like with PHD and ring finger domains 2 is a predictor of survival and a potential therapeutic target in colon cancer. Oncol Rep. 2014;31(4):1802–1810.
   PubMed Web of Science ®Google Scholar
• Li L, Duan Q, Zeng Z, et al. UHRF2 promotes intestinal tumorigenesis through stabilization of TCF4 mediated Wnt/beta-catenin signaling. Int J Cancer. 2020;147(8):2239–2252.
   PubMed Web of Science ®Google Scholar
• Feng Z, Liu Z, Peng K, Wu W. A Prognostic Model Based on Nine DNA Methylation-Driven Genes Predicts Overall Survival for Colorectal Cancer. Front Genet. 2021;12:779383.
   PubMed Web of Science ®Google Scholar
• Shan L, Li T, Gu W, et al. Application of Prognostic Models Based on Psoas Muscle Index, Stage, Pathological Grade, and Preoperative Carcinoembryonic Antigen Level in Stage II-III Colorectal Cancer Patients Undergoing Adjuvant Chemotherapy. J Oncol. 2022;2022:6851900.
   PubMed Web of Science ®Google Scholar
• Chen Y, Li H. Prognostic and Predictive Models for Left- and Right- Colorectal Cancer Patients: a Bioinformatics Analysis Based on Ferroptosis-Related Genes. Front Oncol. 2022;12:833834.
   PubMed Web of Science ®Google Scholar
• Koi M, Carethers J. The colorectal cancer immune microenvironment and approach to immunotherapies. Future Oncology. 2017;13(18):1633–1647.
   PubMed Web of Science ®Google Scholar
• Pham T, Spaulding C, Munshi H. Controlling TIME: how MNK Kinases Function to Shape Tumor Immunity. Cancers. 2020;12(8):2096.
   PubMed Web of Science ®Google Scholar
• Chen Y, Zheng X, Wu C. The Role of the Tumor Microenvironment and Treatment Strategies in Colorectal Cancer. Front Immunol. 2021;12:792691.
   PubMed Web of Science ®Google Scholar
• Halama N, Braun M, Kahlert C, et al. Natural killer cells are scarce in colorectal carcinoma tissue despite high levels of chemokines and cytokines. Clin Cancer Res. 2011;17(4):678–689.
   PubMed Web of Science ®Google Scholar
• Rocca Y, Roberti M, Arriaga J, et al. Altered phenotype in peripheral blood and tumor-associated NK cells from colorectal cancer patients. Innate Immun. 2013;19(1):76–85.
   PubMed Web of Science ®Google Scholar
• Cassetta L, P JW. Tumor-associated macrophages. Curr Biol. 2020;30(6):R246–R248.
   PubMed Web of Science ®Google Scholar
• Fu XT, Dai Z, Song K, et al. Macrophage-secreted IL-8 induces epithelial-mesenchymal transition in hepatocellular carcinoma cells by activating the JAK2/STAT3/Snail pathway. Int J Oncol. 2015;46(2):587–596.
   PubMed Web of Science ®Google Scholar
• Carlsen L, Huntington KE, El-Deiry WS. Immunotherapy for Colorectal Cancer: mechanisms and Predictive Biomarkers. Cancers. 2022;14(4):54.
   Web of Science ®Google Scholar
• Ye L, Zhang T, Kang Z, et al. Tumor-Infiltrating Immune Cells Act as a Marker for Prognosis in Colorectal Cancer. Front Immunol. 2019;10:2368.
   PubMed Web of Science ®Google Scholar
• Marcus L, Lemery SJ, Keegan P. FDA Approval Summary: pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors. Clin Cancer Res. 2019;25(13):3753–3758.
   PubMed Web of Science ®Google Scholar
• Overman MJ, McDermott R, Leach JL, et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, Phase 2 study. Lancet Oncol. 2017;18(9):1182–1191.
   PubMed Web of Science ®Google Scholar